Transaction in Own Shares

Summary by AI ^BETAClose X

Craneware plc has announced the purchase of 42,302 of its ordinary shares on the London Stock Exchange through Peel Hunt LLP, with the weighted average price per share being 1,364.95 pence, ranging from 1,355.00 to 1,375.00 pence. Following this transaction, the company will hold 287,830 shares in treasury, leaving 35,254,339 ordinary shares in issue, which represents the total voting rights. This share buyback is part of a programme announced on 16 March 2026.

Disclaimer*

Craneware plc

25 March 2026

Craneware plc
("Craneware", or the "Company")
Transaction in Own Shares

Craneware (AIM: CRW.L), a leader in healthcare financial performance solutions, announces it has purchased the following number of its Ordinary Shares of 1p each through Peel Hunt LLP on the London Stock Exchange.

Date of purchase	23 March 2026
Number of ordinary shares purchased:	42,302
Lowest price per share (pence):	1,355.00
Highest price per share (pence):	1,375.00
Weighted average price per day (pence):	1,364.95

The Company will hold the purchased shares in Treasury. Following the purchase of these shares, the Company will have 35,254,339 Ordinary Shares in issue (excluding Treasury shares), and the Company will hold 287,830 Ordinary Shares in Treasury.

The figure of 35,254,339 represents the total voting rights in the Company and may be used by shareholders as the denominator for calculating whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The table below contains detailed information about the purchases made as part of the buyback programme which was announced by the Company on 16 March 2026 (the "Programme").

Aggregate information:

Venue	Volume Weighted Average Price (p)	Aggregated Volume	Lowest price paid per share (p)	Highest price paid per share (p)
AIMX	1,364.95	42,302	1,355.00	1,375.00

Schedule of Purchases - Individual Transactions

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 as it forms part of UK law, a full breakdown of the individual trades made by Peel Hunt on behalf of the Company as part of the Programme is detailed below:

Number of shares purchased	Transaction price (pence)	Venue	Time of each trade	Transaction Reference Number
10,000	1,355.00	AIMX	11:43:25	00191193258TRLO0
15,000	1,360.00	AIMX	11:47:08	00191194062TRLO0
17,302	1,375.00	AIMX	13:23:37	00191206745TRLO0

For further information please contact:

Craneware plc	+44 (0)131 550 3100
Keith Neilson, CEO
Craig Preston, CFO

Alma Strategic Communications	+44 (0)20 3405 0205
Caroline Forde, Kinvara Verdon, Louisa El-Ahwal	craneware@almastrategic.com

Peel Hunt (NOMAD and Joint Broker)	+44 (0)20 7418 8900
Neil Patel, Benjamin Cryer, Kate Bannatyne

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus^® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deep healthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering better outcomes for the communities they serve - today and in the future. Together, we are transforming the business of healthcare.

Learn more at www.thecranewaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END